P2RY12 and Thrombocytopenia: We compared the 3-years clinical outcomes of Korean AMI patients with baseline thrombocytopenia administered potent P2Y12 inhibitors (group A) and those of Korean AMI patients with baseline thrombocytopenia administered clopidogrel (group B).